Meleah Hilton, PA
Physician Assistant · Shelby, NCNPI 1760787618
Payments from drug & device makers
Across 295 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$884
- Novo Nordisk$372
- GSK$362
- Novartis$359
- Biohaven Pharmaceutical Holding Company Ltd.$351
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$317
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,800100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $884 |
| Novo Nordisk | 27 | $372 |
| GSK | 7 | $362 |
| Novartis | 19 | $359 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $351 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $317 |
| AstraZeneca | 19 | $288 |
| Amarin Pharma, Inc. | 14 | $282 |
| Sanofi-aventis U.S. LLC | 14 | $263 |
| Lilly USA, LLC | 18 | $259 |
| Amgen | 14 | $220 |
| Boehringer Ingelheim | 9 | $155 |
| Bayer | 9 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $112 |
| Biohaven Pharmaceuticals, Inc. | 6 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Abbott | 2 | $44 |
| Johnson & Johnson | 2 | $35 |
| Astellas Pharma US Inc | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$125
- TRELEGY ELLIPTA$100
How this compares
$4,800 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 12 | $574,070 |
| OzempicSemaglutide | 89 | $117,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $74,946 |
| MounjaroTirzepatide | 58 | $71,470 |
| FarxigaDapagliflozin Propanediol | 67 | $67,575 |
| JardianceEmpagliflozin | 35 | $55,403 |
| LinzessLinaclotide | 46 | $50,282 |
| EliquisApixaban | 66 | $49,920 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $44,332 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $41,392 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $36,850 |
| TrulicityDulaglutide | 20 | $30,050 |
| XareltoRivaroxaban | 26 | $29,708 |
| MyrbetriqMirabegron | 28 | $24,924 |
| CreonLipase/Protease/Amylase | 14 | $23,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Trintellix | $112 | $582,62728 claims |
| Novo NordiskOzempic | $372 | $117,70989 claims |
| Lilly USA, LLCMounjaro, Trulicity | $259 | $101,52078 claims |
| AbbVieLinzess, Creon, Ubrelvy, Synthroid | $884 | $88,176112 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Brilinta | $288 | $83,03598 claims |
| GSKTrelegy Ellipta | $362 | $74,94675 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $155 | $62,30848 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $263 | $44,33235 claims |
| Johnson & JohnsonXarelto | $35 | $29,70826 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $24,92428 claims |
| NovartisEntresto | $359 | $22,71032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Shelby
- Taylor SzucsShelby$22K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.